After a Phase III readout for the centerpiece of its $21 billion Immunomedics acquisition underwhelmed Wall Street, Gilead is bringing out the axe.
The California company is planning to lay off 114 staffers from its Morris Plains, NJ location in three waves later this year, according to a Click to view original post
